Global stocks slumped in a tech-fueled selloff on Tuesday, with investors unnerved by growing debt-funded AI spending, the prospect of a more hawkish U.S. rate outlook, and tightening financial conditions from a stronger dollar and higher U.S. bond yields.
As the world marks the passing of former Federal Reserve Chair Alan Greenspan, who died on Monday aged 100, it’s almost fitting that the U.S. central bank is entering a period of “less is more” when it comes to communications — something the “maestro” himself would have approved of.
Elon Musk’s SpaceX has launched a five-tranche notes offering aimed at raising at least $25 billion, a source familiar with the matter said on Tuesday, as the newly public company seeks funding for its capital-intensive AI expansion.
The Republican-majority U.S. Senate backed legislation on Tuesday to halt U.S. military action against Iran, but it was not immediately clear how it would affect the war as President Donald Trump’s administration negotiates a peace agreement with the Islamic republic.
Russia has accused the United States of failing to deliver on “understandings” reached between presidents Vladimir Putin and Donald Trump at a summit in Alaska last August, a shift that suggests growing frustration in Moscow.
An evacuation plan to enable hundreds of ships with some 11,000 seafarers stranded in the Gulf to sail through the Strait of Hormuz is underway after Iran and the U.S. reached a ceasefire deal, the United Nations’ shipping agency said on Tuesday.
Just one in four Americans believes President Donald Trump’s war with Iran was worth its costs and a majority worry that a truce with Tehran is unlikely to last, a Reuters/Ipsos poll found.
SpaceX’s stock extended its wild ride on Tuesday, briefly falling below its first-day opening price before rebounding on an otherwise weak day for the tech sector – sharpening Wall Street’s focus on the shifting balance between buyers and sellers of the volatile shares.
New York, Maryland and Utah each hold primaries.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said.